Phytoselective therapy is a method of choice for the treatment of mastopathy in combination with premenstrual syndrome

Autor: O. V. Gryshchenko, V. V. Bobrytska
Jazyk: English<br />Russian<br />Ukrainian
Rok vydání: 2020
Předmět:
Zdroj: Репродуктивная эндокринология, Vol 0, Iss 55, Pp 79-89 (2020)
Druh dokumentu: article
ISSN: 2309-4117
2411-1295
DOI: 10.18370/2309-4117.2020.55.79-89
Popis: Breast dishormonal diseases and premenstrual syndrome (PMS) have a common pathogenetic mechanism: hyperprolactinemia, decreased progesterone levels, thyroid dysfunction, increased cortisol including as a result of stress, dysphoric disorders. Purpose of the study was to optimize monotherapy of breast dishormonal diseases in combination with PMS with phytoselective complex Tazalok™ and to compare the clinical efficacy with traditional therapy with Vitex agnus-castus derivative. Materials and methods. 120 women aged 22–39 years were observed into 2 groups: group I – 60 patients who received monotherapy Tazalok™ for 3 months; group II – 60 patients who received monotherapy with derivative of Vitex agnus-castus. Data analysis was performed after 1 and 3 months of treatment. Sex hormones, thyroid, gonadotropic hormones levels were determined. Ultrasound examination with color Doppler flow mapping of mammary glands, pelvic organs, and thyroid was performed. Dysphoric disorders were assessed on the Beck depression scale, pain was assessed on the visual-analog scale (VAS). Results. Group I showed an improvement in hormonal profile, reduction of subjective complaints after 1 month, in group II there was mainly a decrease in prolactin and relative normalization of follicle-stimulating hormone, luteinizing hormone; PMS complaints persisted. By 3 months patients in group I had normalization of all hormonal parameters, including cortisol, thyroid hormones, decreased pathological vascularization of mammary glands, thyroid, and pelvic organs, and a significant reduction in the Beck depressive score and VAS. In group II there was no normalization of cortisol, thyroid hormones, significantly reduced levels of progesterone and luteinizing hormone compared to group I, there was pathological vascularization in the thyroid gland, uterus. Dysphoric disorders decreased slightly, pain syndrome on the VAS decreased moderately, but the score was higher than among women taking Tazalok™. Conclusions. Tazalok™ directly affects reproductive system and balance of stress hormones, has a therapeutic effect on the thyroid gland. Under its action sonographic picture of hormone-dependent organs was normalized in contrast to the Vitex agnus-castus derivative. Tazalok™ has a pronounced effect on dysphoric disorders of PMS, helps to normalize the neuropsychological and cognitive state, to prevent of psychosomatic disorders.
Databáze: Directory of Open Access Journals
Externí odkaz: